Literature DB >> 25677835

Behçet's disease and comorbidity: internal case reports and literature review.

Zemfira Alekberova1, Vadim Gorodetskiy1, Fatima Izmailova2, Stefka Radenska-Lopovok1, Elnura Talybova1, Margarita Evsikova1, Nikolai Timoshin3, Evgeni Nasonov1.   

Abstract

The aim of this study was to determine the clinical characteristics of two patients with malignancy related to Behçet's disease. We reviewed literary-reported cases of Behçet's disease related to myelodysplastic syndrome, neoplasm and leukemia. Our own observation included two cases of comorbid conditions of Behçet's disease. The first patient with Behçet's disease had been examined concurrent development of intestinal tumor. The second one was diagnosed to have chromic myeloleukemia. The malignant transformation of Behçet's disease patients, both solid and hematological, is rather rare. Further accumulation of relevant date and its analysis will allow to find out the relationship between malignant disease and chemotherapy in Behçet's disease.

Entities:  

Keywords:  Behçet’s disease; Comorbidity; Myelodysplastic syndrome

Mesh:

Year:  2015        PMID: 25677835     DOI: 10.1007/s00296-015-3232-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

Review 1.  Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis--Behçet's syndrome.

Authors:  S Kimura; J Kuroda; T Akaogi; H Hayashi; Y Kobayashi; M Kondo
Journal:  Leuk Lymphoma       Date:  2001-06

2.  Behçet's disease, myelodysplastic syndrome, trisomy 8, gastroenterological involvement--an association.

Authors:  L Eder; M Rozenbaum; N Boulman; E Aayubkhanov; E Wolfovitz; D Zisman; I Rosner
Journal:  Clin Exp Rheumatol       Date:  2005 Jul-Aug       Impact factor: 4.473

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

4.  Skin hyperreactivity of Behçet's patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders.

Authors:  T Budak-Alpdogan; O Alpdogan; H Direskeneli; T Ergun; A Oztürk; A Günay; S Yavuz; N Uskent; T Akoğlu
Journal:  Br J Rheumatol       Date:  1998-11

5.  Colon cancer arising in an ulcer scar due to intestinal Behçet's disease.

Authors:  Masayoshi Yamada; Hisakazu Shiroeda; Tomoe Nomura; Ranji Hayashi; Katsuaki Sato; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  Intern Med       Date:  2011-03-01       Impact factor: 1.271

6.  Behçet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms.

Authors:  T Budak-Alpdoğan; Z Demirçay; O Alpdoğan; H Direskeneli; T Ergun; M Bayik; T Akoğlu
Journal:  Ann Hematol       Date:  1997-01       Impact factor: 3.673

Review 7.  [Behçet's disease with an onset prior to the appearance of chronic myeloid leukemia].

Authors:  D Tassies; F Cervantes; E Feliu; G Cabal; F Martínez Orozco; C Rozman
Journal:  Med Clin (Barc)       Date:  1992-06-06       Impact factor: 1.725

8.  Resolution of Behçet's disease after HLA-mismatched unrelated cord blood transplantation for myelodysplastic syndrome.

Authors:  Akira Tomonari; Arinobu Tojo; Tsutomu Takahashi; Tohru Iseki; Jun Ooi; Satoshi Takahashi; Fumitaka Nagamura; Kaoru Uchimaru; Shigetaka Asano
Journal:  Ann Hematol       Date:  2003-12-02       Impact factor: 3.673

9.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

Review 10.  Behçet disease associated with myelodysplastic syndrome.

Authors:  Yi-Chun Lin; Toong-Hua Liang; Hsiao-Ning Chang; Jeong-Shi Lin; Hsiao-Yi Lin
Journal:  J Clin Rheumatol       Date:  2008-06       Impact factor: 3.517

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.